Nothing Special   »   [go: up one dir, main page]

EP1606301A4 - Aptamer therapeutics useful in ocular pharmacotherapy - Google Patents

Aptamer therapeutics useful in ocular pharmacotherapy

Info

Publication number
EP1606301A4
EP1606301A4 EP04704120A EP04704120A EP1606301A4 EP 1606301 A4 EP1606301 A4 EP 1606301A4 EP 04704120 A EP04704120 A EP 04704120A EP 04704120 A EP04704120 A EP 04704120A EP 1606301 A4 EP1606301 A4 EP 1606301A4
Authority
EP
European Patent Office
Prior art keywords
pharmacotherapy
ocular
therapeutics useful
aptamer therapeutics
aptamer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04704120A
Other languages
German (de)
French (fr)
Other versions
EP1606301A2 (en
Inventor
David Epstein
Dilara Grate
Jeffrey Kurz
Nicholas Marsh
Thomas G Mccauley
Charles Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Archemix Corp
Original Assignee
Archemix Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Archemix Corp filed Critical Archemix Corp
Publication of EP1606301A2 publication Critical patent/EP1606301A2/en
Publication of EP1606301A4 publication Critical patent/EP1606301A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/317Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/318Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3183Diol linkers, e.g. glycols or propanediols
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3222'-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EP04704120A 2003-01-21 2004-01-21 Aptamer therapeutics useful in ocular pharmacotherapy Withdrawn EP1606301A4 (en)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US44134703P 2003-01-21 2003-01-21
US441347P 2003-01-21
US46309503P 2003-04-15 2003-04-15
US463095P 2003-04-15
US46417903P 2003-04-21 2003-04-21
US464179P 2003-04-21
US46505503P 2003-04-23 2003-04-23
US465055P 2003-04-23
US46962803P 2003-05-08 2003-05-08
US469628P 2003-05-08
US47468003P 2003-05-29 2003-05-29
US474680P 2003-05-29
US49101903P 2003-07-29 2003-07-29
US491019P 2003-07-29
US51207103P 2003-10-17 2003-10-17
US512071P 2003-10-17
US53704504P 2004-01-16 2004-01-16
US53720104P 2004-01-16 2004-01-16
US537201P 2004-01-16
US537045P 2004-01-16
PCT/US2004/001661 WO2004064760A2 (en) 2003-01-21 2004-01-21 Aptamer therapeutics useful in ocular pharmacotherapy

Publications (2)

Publication Number Publication Date
EP1606301A2 EP1606301A2 (en) 2005-12-21
EP1606301A4 true EP1606301A4 (en) 2006-06-14

Family

ID=32777434

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04704120A Withdrawn EP1606301A4 (en) 2003-01-21 2004-01-21 Aptamer therapeutics useful in ocular pharmacotherapy

Country Status (5)

Country Link
EP (1) EP1606301A4 (en)
JP (1) JP2006516288A (en)
AU (1) AU2004206955A1 (en)
CA (1) CA2513004A1 (en)
WO (1) WO2004064760A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070166741A1 (en) 1998-12-14 2007-07-19 Somalogic, Incorporated Multiplexed analyses of test samples
US10100316B2 (en) 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US8039443B2 (en) 2002-11-21 2011-10-18 Archemix Corporation Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
WO2005110489A2 (en) * 2004-04-13 2005-11-24 (Osi) Eyetech, Inc. Nucleic acid aptamers conjugated to high molecular weight steric groups
EP2436391A3 (en) * 2004-11-02 2012-07-04 Archemix LLC Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
WO2006119643A1 (en) * 2005-05-12 2006-11-16 Replicor Inc. Anti-ocular angiogenesis molecules and their uses
HUE026496T2 (en) * 2006-03-08 2016-06-28 Archemix Llc Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
CA3027780A1 (en) 2008-09-22 2010-03-25 Phio Pharmaceuticals Corp. Reduced size self-delivering rnai compounds
JP2010100615A (en) * 2008-09-25 2010-05-06 Santen Pharmaceut Co Ltd Prophylactic or curative agent for retinal disease including polyalkylene glycol as active ingredient
US9745574B2 (en) 2009-02-04 2017-08-29 Rxi Pharmaceuticals Corporation RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US8993715B2 (en) * 2009-07-06 2015-03-31 Canon Kabushiki Kaisha Labeled protein and method for obtaining the same
JP6041373B2 (en) * 2010-02-01 2016-12-07 Necソリューションイノベータ株式会社 Aptamer molecule that binds to TNF-α
RU2615143C2 (en) 2010-03-24 2017-04-04 Адвирна Self-delivered rnai compounds of reduced size
WO2011119871A1 (en) * 2010-03-24 2011-09-29 Rxi Phrmaceuticals Corporation Rna interference in ocular indications
JP6587934B2 (en) 2012-03-28 2019-10-09 ソマロジック・インコーポレーテッド PDGF and VEGF binding aptamers and their use in the treatment of diseases mediated by PDGF and VEGF
CN105431204A (en) * 2013-07-12 2016-03-23 奥普索特克公司 Methods for treating or preventing ophthalmological conditions
JP6630273B2 (en) 2013-09-09 2020-01-15 ソマロジック・インコーポレーテッド PDGF and VEGF aptamers with improved stability and their use in the treatment of PDGF and VEGF mediated diseases and disorders
US20160304875A1 (en) * 2013-12-04 2016-10-20 Rxi Pharmaceuticals Corporation Methods for treatment of wound healing utilizing chemically modified oligonucleotides
CA2947270A1 (en) 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treating cancer using nucleic acids targeting mdm2 or mycn
AU2016364431B2 (en) 2015-12-04 2020-08-27 Zenyaku Kogyo Co., Ltd. Anti-IL-17 aptamer having improved retention in blood
CA3012718A1 (en) 2016-02-08 2017-08-17 Vitrisa Therapeutics, Inc. Compositions with improved intravitreal half-life and uses thereof
WO2018148333A1 (en) * 2017-02-08 2018-08-16 Vitrisa Therapeutics, Inc. Compositions with improved intravitreal half-life and uses thereof
SG11202006296YA (en) 2018-01-19 2020-08-28 Cytokinetics Inc Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
EP3814342B1 (en) 2018-06-26 2022-07-27 Cytokinetics, Inc. Cardiac sarcomere inhibitors
WO2020120256A1 (en) * 2018-12-11 2020-06-18 Université De Strasbourg Aptamer and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001009156A1 (en) * 1999-07-29 2001-02-08 Gilead Sciences, Inc. HIGH AFFINITY TGFη NUCLEIC ACID LIGANDS AND INHIBITORS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811533A (en) * 1990-06-11 1998-09-22 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
US6458559B1 (en) * 1998-04-22 2002-10-01 Cornell Research Foundation, Inc. Multivalent RNA aptamers and their expression in multicellular organisms
JP2003530146A (en) * 2000-02-10 2003-10-14 マサチューセッツ・アイ・アンド・イア・インファーマリー Photodynamic therapy to treat eye conditions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001009156A1 (en) * 1999-07-29 2001-02-08 Gilead Sciences, Inc. HIGH AFFINITY TGFη NUCLEIC ACID LIGANDS AND INHIBITORS

Also Published As

Publication number Publication date
CA2513004A1 (en) 2004-08-05
WO2004064760A3 (en) 2005-10-27
WO2004064760A2 (en) 2004-08-05
AU2004206955A1 (en) 2004-08-05
EP1606301A2 (en) 2005-12-21
JP2006516288A (en) 2006-06-29

Similar Documents

Publication Publication Date Title
EP1606301A4 (en) Aptamer therapeutics useful in ocular pharmacotherapy
GB0308841D0 (en) Improvements in convenience rolls
GB0307802D0 (en) Selecting functions in context
GB2401029B (en) Improvements in furniture
IL165219A0 (en) Moisture-management in hydrophilic fibers
GB0306367D0 (en) Improvements in or relating to stairlifts
GB0328314D0 (en) Therapeutics
GB2423462B (en) Improvements in garments
GB2401161B (en) Improvements in movement controls
GB0428089D0 (en) Improvements in automotive technology
GB0328262D0 (en) Improvements in movement controls
GB2418496B (en) Improvements in or relating to eyewear
GB2417734B (en) Improvements in worktops
GB0418260D0 (en) Improvements in mirrors
GB0324811D0 (en) Improvements in magnetopolariscopes
GB0412558D0 (en) Improvements in vehicle progress indication
GB0419498D0 (en) Improvements in worktops
GB0512768D0 (en) Recreational article
IL163758A0 (en) Improvments in showers
GB0423631D0 (en) Improvements in autostereoscopic design
AU2004902291A0 (en) Improvements in clothing
GB0415274D0 (en) Improvements in curtains
GB0423607D0 (en) Improvements in autostereoscopic displays
GB0423629D0 (en) Improvements in autostereoscopic displays
GB0302046D0 (en) KIT - Keep in touch

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050818

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/11 20060101AFI20060215BHEP

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20060515

17Q First examination report despatched

Effective date: 20070627

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080108